Intraoperative High-Dose Dexamethasone in Cardiac Surgery and the Risk of Rethoracotomy Dirk van Osch, MD, Jan M. Dieleman, MD, Hendrik M. Nathoe, MD, PhD, Marc P. Boasson, BS, Jolanda Kluin, MD, PhD, Jeroen J.H. Bunge, MD, Arno P. Nierich, MD, Peter M. Rosseel, MD, Joost M. van der Maaten, MD, Jan Hofland, MD, PhD, Jan C. Diephuis, MD, Fellery de Lange, MD, Christa Boer, PhD, Diederik van Dijk, MD, PhD The Annals of Thoracic Surgery Volume 100, Issue 6, Pages 2237-2242 (December 2015) DOI: 10.1016/j.athoracsur.2015.06.025 Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Study flowchart. (DECS = Dexamethasone for Cardiac Surgery.) The Annals of Thoracic Surgery 2015 100, 2237-2242DOI: (10.1016/j.athoracsur.2015.06.025) Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Survival curves for freedom from surgical reintervention: dexamethasone group (green line) and placebo group (blue line). The Annals of Thoracic Surgery 2015 100, 2237-2242DOI: (10.1016/j.athoracsur.2015.06.025) Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions